Results 61 to 70 of about 1,721,070 (243)

IL-12 [PDF]

Science-Business eXchange, 2010
Karim Makhlouf, Samia J Khoury, Howard L Weiner   +2 more
openaire   +2 more sources

Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice

Frontiers in Immunology
Hepatocellular carcinoma (HCC) and solid cancers with liver metastases are indications with high unmet medical need. Interleukin-12 (IL-12) is a proinflammatory cytokine with substantial anti-tumor properties, but its therapeutic potential has not been ...
Matthias J. Düchs, Ramona F. Kratzer, Pablo Vieyra-Garcia, Benjamin Strobel, Tanja Schönberger, Peter Groß, Ghaith Aljayyoussi, Aradhana Gupta, Isabel Lang, Holger Klein, Sandra Martinez Morilla, Stefan Hopf, John Park, Sebastian Kreuz, Matthias Klugmann, Frederik H. Igney   +15 more
doaj   +1 more source

Staphylococcus aureus bacteremia with iliac artery endarteritis in a patient receiving ustekinumab

BMC Infectious Diseases, 2016
Background Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12 and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis.
Insa Joost, Johannes Steinfurt, Philipp T. Meyer, Winfried V. Kern, Siegbert Rieg   +4 more
doaj   +1 more source

Incidence and Severity of Carboplatin‐Associated Hearing Loss in Children With Cancer Assessed by the SIOP Boston 2012 Ototoxicity Criteria

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla, Sean Carter, Andrew Wood, Sandra Staffieri, Andrew Dodgshun, David D. Eisenstat, Michael Sullivan   +6 more
wiley   +1 more source

Enhanced gut barrier integrity sensitizes colon cancer to immune therapy

OncoImmunology, 2018
Oral IL-10 suppressed tumor growth in the APCmin/+ mouse/Bacteroides fragilis colon cancer model while a similar formulation of IL-12 exacerbated disease.
Neal Bhutiani, Qingsheng Li, Charles D. Anderson, Heather C. Gallagher, Magdia De Jesus, Rajbir Singh, Venkatkrishna R. Jala, Mostafa Fraig, Tao Gu, Nejat K. Egilmez   +9 more
doaj   +1 more source

The TYK2-P1104A Autoimmune Protective Variant Limits Coordinate Signals Required to Generate Specialized T Cell Subsets

Frontiers in Immunology, 2019
TYK2 is a JAK family member that functions downstream of multiple cytokine receptors. Genome wide association studies have linked a SNP (rs34536443) within TYK2 encoding a Proline to Alanine substitution at amino acid 1104, to protection from multiple ...
Jacquelyn A. Gorman, Christian Hundhausen, Mackenzie Kinsman, Tanvi Arkatkar, Eric J. Allenspach, Eric J. Allenspach, Courtnee Clough, Samuel E. West, Kerri Thomas, Kerri Thomas, Ahmet Eken, Socheath Khim, Malika Hale, Malika Hale, Mohamed Oukka, Mohamed Oukka, Mohamed Oukka, Shaun W. Jackson, Shaun W. Jackson, Karen Cerosaletti, Jane H. Buckner, David J. Rawlings, David J. Rawlings, David J. Rawlings   +23 more
doaj   +1 more source

Re‐Irradiation in Pediatric Diffuse Midline Glioma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with recurrent diffuse midline gliomas (DMGs) have limited therapeutic options at recurrence. Re‐irradiation (RT2) may be used at progression, but with uncertainty about the benefit. Methods We conducted a multi‐institutional retrospective study of children aged < 18 with DMG treated at three centers (Toronto, Canada ...
Ajay Thomas Alex, Sean P. Hassan, Helen Benghiat, Liam Herbert, Jennifer Adamski, Shivani Bailey, Claire Esler, Louise Brookes, Molly Bamber, Grace Koudou, Karen Waite, Julie Bennett, Anirban Das, Derek S. Tsang   +13 more
wiley   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Development of approaches for cellular immunotherapy of cancer patients

Медицинская иммунология, 2021
To treat the patients with oncological diseases, cellular immunotherapy have been actively developed in recent years. Usage of antitumor adoptive immunotherapy (AIT) based on in vitro activated lymphocytes and natural killer cells (NK cells) is the most ...
Yu. V. Gelm, E. V. Abakushina, I. A. Pasova, L. Yu. Grivtsova   +3 more
doaj  

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source